Abstract
The impairment of growth hormone (GH)/insulin growth factor-1(IGF-1) plays a crucial role in chronic heart failure (CHF). Several studies have shown that patients affected by this condition display a more aggressive disease, with impaired functional capacity and poor outcomes. Interestingly, GH replacement therapy represents a possible future therapeutic option in CHF. In this review, the authors focus on the assessment of the main abnormalities in GH/IGF-1 axis in CHF, the underlying molecular background, and their impact on disease progression and outcomes.
Original language | English |
---|---|
Pages (from-to) | 65-74 |
Number of pages | 10 |
Journal | Heart Failure Clinics |
Volume | 14 |
Issue number | 1 |
DOIs | |
Publication status | E-pub ahead of print - Nov 17 2017 |
Keywords
- Anabolic deficiency
- Biomarker
- Chronic heart failure
- Growth hormone
- IGF-1
- Outcomes
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine